Request for Information: The National Toxicology Program Requests Information on Use, Human Exposure, and Toxicity of Vinpocetine, 58548 [2013-23212]
Download as PDF
58548
Federal Register / Vol. 78, No. 185 / Tuesday, September 24, 2013 / Notices
Contact Person: Carol Hamelink, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4192,
MSC 7850, Bethesda, MD 20892, (301) 213–
9887, hamelinc@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR 13–
213: Outcome Measures for Use in Treatment
Trials for Individuals with Intellectual and
Developmental Disabilities (R01).
Date: October 18, 2013.
Time: 1:00 p.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: The William F. Bolger Center, 9600
Newbridge Drive, Potomac, MD 20854.
Contact Person: Jane A DoussardRoosevelt, Ph.D., Scientific Review Officer,
Center for Scientific Review, National
Institutes of Health, 6701 Rockledge Drive,
Room 3184, MSC 7848, Bethesda, MD 20892,
(301) 435–4445, doussarj@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR 13–008
Robotic Bioanalytical Shared
Instrumentation.
Date: October 18, 2013.
Time: 2:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Marie-Jose Belanger, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5181,
MSC 7804, Bethesda, MD 20892, belangerm@
csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: September 18, 2013.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2013–23082 Filed 9–23–13; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Request for Information: The National
Toxicology Program Requests
Information on Use, Human Exposure,
and Toxicity of Vinpocetine
To facilitate the design of
toxicological studies for vinpocetine
(CAS RN: 42971–09–5), the National
Toxicology Program (NTP) at the
National Institute of Environmental
Health Sciences (NIEHS) requests the
submission of available information
regarding (1) exposure,
pharmacokinetics, toxicity, safety, or
mstockstill on DSK4VPTVN1PROD with NOTICES
SUMMARY:
VerDate Mar<15>2010
19:49 Sep 23, 2013
Jkt 229001
efficacy in humans; (2) production, use,
and consumption patterns in the United
States; (3) genotoxicity, repeated dose
toxicity, prenatal developmental
toxicity, reproductive toxicity, chronic
toxicity, and carcinogenicity studies in
experimental animals; and (4) any other
information relative to the safety or
toxicity of vinpocetine not listed above.
DATES: The deadline for receipt of
information is November 4, 2013.
ADDRESSES: Submission of information
via email to surhi@niehs.nih.gov is
preferred.
Dr.
Inok Surh, Research Fellow, Toxicology
Branch, Division of the NTP, NIH/
NIEHS, P.O. Box 12233, MD K2–12,
Research Triangle Park, NC 27709.
Phone: (919) 541–3862, Fax: (919) 541–
4255, Email: surhi@niehs.nih.gov. Hand
Delivery/Courier: 530 Davis Drive,
Room 2067, Morrisville, NC 27560.
SUPPLEMENTARY INFORMATION:
Background: The National Cancer
Institute nominated the dietary
supplement vincamine to the NTP for
genotoxicity, subchronic toxicity, and
mechanistic studies due to a lack of
information on its potential toxicity
following long-term administration
(https://ntp.niehs.nih.gov/go/1123).
Currently, vincamine appears to be
infrequently marketed in the United
States, while vinpocetine, a semisynthetic derivative of vincamine, is
widely available as a dietary
supplement. In a review of the available
literature, the NTP found that published
data on genotoxicity, carcinogenicity,
and reproductive and developmental
toxicity for vinpocetine are very limited
(https://ntp.niehs.nih.gov/ntp/htdocs/
Chem_Background/ExSumPdf/
Vinpocetine091613_508.pdf). To
address the lack of data and potential
widespread exposure, the NTP is
developing a research program for
toxicological characterization of
vinpocetine.
Request for Information: The NTP
seeks to identify relevant information on
the use, human exposure, and toxicity
of vinpocetine in humans and
experimental animal models. In
particular, information is sought from
unpublished or ongoing research studies
or other sources not readily available.
Any information provided by
respondents will be used to supplement
information the NTP has already
gathered, and will be considered during
the design of one or more types of
experimental toxicology studies of
vinpocetine. Specifically, the NTP
requests the submission of information
regarding:
FOR FURTHER INFORMATION CONTACT:
PO 00000
Frm 00038
Fmt 4703
Sfmt 9990
(1) Exposure, pharmacokinetics,
toxicity, safety, or efficacy of
vinpocetine in humans. (2) Production,
use, and consumption patterns of
vinpocetine in the United States. (3)
Genotoxicity, repeated dose toxicity,
prenatal developmental toxicity,
reproductive toxicity, chronic toxicity,
and carcinogenicity studies of
vinpocetine in experimental animals. (4)
Any other information relative to the
safety or toxicity of vinpocetine not
listed above.
Responses are requested from all
interested parties, such as the research
community, health professionals,
educators, policy makers, industry, and
the public. Responses to this request for
information are voluntary. The NTP
does not intend to publish a summary
of responses received or any other
information provided. Despite this, no
proprietary, classified, confidential, or
sensitive information should be
included in your response. This request
for information is for planning purposes
only and is not a solicitation for
applications or an obligation on the part
of the U.S. Government to provide
support for any ideas identified in
response to it. Please note that the U.S.
Government will not pay for the
preparation of any information
submitted or for its use of that
information. Persons submitting
information should include their name,
affiliation, mailing address, phone, fax,
email address, and sponsoring
organization (if any) with the
submission. The deadline for receipt of
the requested information is November
4, 2013.
Background Information on the NTP:
The NTP is an interagency program
established in 1978 (43 FR 53060) to
strengthen the Department’s activities in
toxicology research and testing, and
develop and validate new and better
testing methods. Other activities of the
program focus on strengthening the
science base in toxicology and
providing information about potentially
toxic chemicals to health regulatory and
research agencies, scientific and
medical communities, and the public.
The NTP is located administratively at
the NIEHS. Information about the NTP
and NIEHS is found at https://
www.niehs.nih.gov and https://
ntp.niehs.nih.gov, respectively.
Dated: September 18, 2013.
John R. Bucher,
Associate Director, National Toxicology
Program.
[FR Doc. 2013–23212 Filed 9–23–13; 8:45 am]
BILLING CODE 4140–01–P
E:\FR\FM\24SEN1.SGM
24SEN1
Agencies
[Federal Register Volume 78, Number 185 (Tuesday, September 24, 2013)]
[Notices]
[Page 58548]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-23212]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Request for Information: The National Toxicology Program Requests
Information on Use, Human Exposure, and Toxicity of Vinpocetine
SUMMARY: To facilitate the design of toxicological studies for
vinpocetine (CAS RN: 42971-09-5), the National Toxicology Program (NTP)
at the National Institute of Environmental Health Sciences (NIEHS)
requests the submission of available information regarding (1)
exposure, pharmacokinetics, toxicity, safety, or efficacy in humans;
(2) production, use, and consumption patterns in the United States; (3)
genotoxicity, repeated dose toxicity, prenatal developmental toxicity,
reproductive toxicity, chronic toxicity, and carcinogenicity studies in
experimental animals; and (4) any other information relative to the
safety or toxicity of vinpocetine not listed above.
DATES: The deadline for receipt of information is November 4, 2013.
ADDRESSES: Submission of information via email to surhi@niehs.nih.gov
is preferred.
FOR FURTHER INFORMATION CONTACT: Dr. Inok Surh, Research Fellow,
Toxicology Branch, Division of the NTP, NIH/NIEHS, P.O. Box 12233, MD
K2-12, Research Triangle Park, NC 27709. Phone: (919) 541-3862, Fax:
(919) 541-4255, Email: surhi@niehs.nih.gov. Hand Delivery/Courier: 530
Davis Drive, Room 2067, Morrisville, NC 27560.
SUPPLEMENTARY INFORMATION:
Background: The National Cancer Institute nominated the dietary
supplement vincamine to the NTP for genotoxicity, subchronic toxicity,
and mechanistic studies due to a lack of information on its potential
toxicity following long-term administration (https://ntp.niehs.nih.gov/go/1123). Currently, vincamine appears to be infrequently marketed in
the United States, while vinpocetine, a semi-synthetic derivative of
vincamine, is widely available as a dietary supplement. In a review of
the available literature, the NTP found that published data on
genotoxicity, carcinogenicity, and reproductive and developmental
toxicity for vinpocetine are very limited (https://ntp.niehs.nih.gov/ntp/htdocs/Chem_Background/ExSumPdf/Vinpocetine091613_508.pdf). To
address the lack of data and potential widespread exposure, the NTP is
developing a research program for toxicological characterization of
vinpocetine.
Request for Information: The NTP seeks to identify relevant
information on the use, human exposure, and toxicity of vinpocetine in
humans and experimental animal models. In particular, information is
sought from unpublished or ongoing research studies or other sources
not readily available. Any information provided by respondents will be
used to supplement information the NTP has already gathered, and will
be considered during the design of one or more types of experimental
toxicology studies of vinpocetine. Specifically, the NTP requests the
submission of information regarding:
(1) Exposure, pharmacokinetics, toxicity, safety, or efficacy of
vinpocetine in humans. (2) Production, use, and consumption patterns of
vinpocetine in the United States. (3) Genotoxicity, repeated dose
toxicity, prenatal developmental toxicity, reproductive toxicity,
chronic toxicity, and carcinogenicity studies of vinpocetine in
experimental animals. (4) Any other information relative to the safety
or toxicity of vinpocetine not listed above.
Responses are requested from all interested parties, such as the
research community, health professionals, educators, policy makers,
industry, and the public. Responses to this request for information are
voluntary. The NTP does not intend to publish a summary of responses
received or any other information provided. Despite this, no
proprietary, classified, confidential, or sensitive information should
be included in your response. This request for information is for
planning purposes only and is not a solicitation for applications or an
obligation on the part of the U.S. Government to provide support for
any ideas identified in response to it. Please note that the U.S.
Government will not pay for the preparation of any information
submitted or for its use of that information. Persons submitting
information should include their name, affiliation, mailing address,
phone, fax, email address, and sponsoring organization (if any) with
the submission. The deadline for receipt of the requested information
is November 4, 2013.
Background Information on the NTP: The NTP is an interagency
program established in 1978 (43 FR 53060) to strengthen the
Department's activities in toxicology research and testing, and develop
and validate new and better testing methods. Other activities of the
program focus on strengthening the science base in toxicology and
providing information about potentially toxic chemicals to health
regulatory and research agencies, scientific and medical communities,
and the public. The NTP is located administratively at the NIEHS.
Information about the NTP and NIEHS is found at https://www.niehs.nih.gov and https://ntp.niehs.nih.gov, respectively.
Dated: September 18, 2013.
John R. Bucher,
Associate Director, National Toxicology Program.
[FR Doc. 2013-23212 Filed 9-23-13; 8:45 am]
BILLING CODE 4140-01-P